Dyne Therapeutics (NASDAQ:DYN) Downgraded to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Dyne Therapeutics (NASDAQ:DYN) from a sell rating to a strong sell rating in a report released on Saturday.

Other equities research analysts have also recently issued reports about the company. JPMorgan Chase & Co. dropped their price objective on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Morgan Stanley dropped their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Finally, HC Wainwright dropped their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.

Dyne Therapeutics Trading Down 0.9%

Dyne Therapeutics stock opened at $17.39 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25. Dyne Therapeutics has a one year low of $8.06 and a one year high of $25.00. The stock has a market capitalization of $2.87 billion, a PE ratio of -4.91 and a beta of 1.08. The business’s fifty day moving average is $17.89 and its 200 day moving average is $18.53.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02). On average, sell-side analysts predict that Dyne Therapeutics will post -2.94 EPS for the current year.

Insider Activity

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 287,956 shares of the firm’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $19.68, for a total value of $5,666,974.08. Following the transaction, the director directly owned 11,663 shares of the company’s stock, valued at approximately $229,527.84. This trade represents a 96.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner bought 3,000 shares of the company’s stock in a transaction on Friday, March 6th. The stock was purchased at an average cost of $15.06 per share, for a total transaction of $45,180.00. Following the completion of the transaction, the director directly owned 11,500 shares of the company’s stock, valued at approximately $173,190. The trade was a 35.29% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 1,446,188 shares of company stock worth $27,758,128 over the last three months. Insiders own 14.14% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of DYN. Fifth Third Bancorp bought a new position in shares of Dyne Therapeutics in the first quarter worth about $983,000. Darwin Wealth Management LLC raised its stake in shares of Dyne Therapeutics by 34.4% in the first quarter. Darwin Wealth Management LLC now owns 154,862 shares of the company’s stock worth $2,808,000 after buying an additional 39,595 shares during the period. Stephens Inc. AR bought a new position in shares of Dyne Therapeutics in the first quarter worth about $183,000. Inspire Investing LLC bought a new position in shares of Dyne Therapeutics in the first quarter worth about $169,000. Finally, Pictet Asset Management Holding SA raised its stake in shares of Dyne Therapeutics by 49.4% in the first quarter. Pictet Asset Management Holding SA now owns 19,372 shares of the company’s stock worth $351,000 after buying an additional 6,409 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.